

Liver cirrhosis induces renal and liver phospholipase A2 activity in rats.

B S Vishwanath, F J Frey, G Escher, J Reichen, B M Frey

J Clin Invest. 1996;98(2):365-371. <https://doi.org/10.1172/JCI118801>.

Research Article

Maintenance of renal function in liver cirrhosis requires increased synthesis of arachidonic acid derived prostaglandin metabolites. Arachidonate metabolites have been reported to be involved in modulation of liver damage. The purpose of the present study was to establish whether the first enzyme of the prostaglandin cascade synthesis, the phospholipase A2(PLA2) is altered in liver cirrhosis induced by bile duct excision. The mRNA of PLA2(group I and II) and annexin-I a presumptive inhibitor of PLA2 enzyme was measured by PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal standard. The mean mRNA ratio of group II PLA2/GAPDH was increased in liver tissue by 126% ($P < 0.001$) and in kidney tissue by 263% ($P < 0.006$) following induction of liver cirrhosis. The increase in group II PLA2 mRNA in cirrhotic animals was reflected by an increase in PLA2 protein and enzyme activity in both liver and kidney tissues. Since the mRNA of group I PLA2 was not detectable and Group IV PLA2 activity measured in liver and kidney tissue samples was very low and not changed following induction of cirrhosis, it is likely that the major PLA2 activity measured in liver and kidney corresponds to group II PLA2 enzyme. The mean mRNA ratio of annexin-I/GAPDH was increased in liver tissue by 115% ($P < 0.05$) but unchanged in kidney tissue following [...]

Find the latest version:

<https://jci.me/118801/pdf>



Liver Cirrhosis Induces Renal and Liver Phospholipase A₂ Activity in Rats

Bannikuppe S. Vishwanath,* Felix J. Frey,* Geneviève Escher,* Jürg Reichen,‡ and Brigitte M. Frey*

*Division of Nephrology, Department of Medicine, and ‡Department of Clinical Pharmacology, University of Berne, 3010 Berne, Switzerland

Abstract

Maintenance of renal function in liver cirrhosis requires increased synthesis of arachidonic acid derived prostaglandin metabolites. Arachidonate metabolites have been reported to be involved in modulation of liver damage. The purpose of the present study was to establish whether the first enzyme of the prostaglandin cascade synthesis, the phospholipase A₂(PLA₂) is altered in liver cirrhosis induced by bile duct excision. The mRNA of PLA₂(group I and II) and annexin-I a presumptive inhibitor of PLA₂ enzyme was measured by PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal standard. The mean mRNA ratio of group II PLA₂/GAPDH was increased in liver tissue by 126% ($P < 0.001$) and in kidney tissue by 263% ($P < 0.006$) following induction of liver cirrhosis. The increase in group II PLA₂ mRNA in cirrhotic animals was reflected by an increase in PLA₂ protein and enzyme activity in both liver and kidney tissues. Since the mRNA of group I PLA₂ was not detectable and Group IV PLA₂ activity measured in liver and kidney tissue samples was very low and not changed following induction of cirrhosis, it is likely that the major PLA₂ activity measured in liver and kidney corresponds to group II PLA₂ enzyme. The mean mRNA ratio of annexin-I/GAPDH was increased in liver tissue by 115% ($P < 0.05$) but unchanged in kidney tissue following induction of cirrhosis. The protein content of annexin-I and -V were not affected by bile duct excision in liver and kidney tissue indicating that upregulation of group II PLA₂ activity was not due to downregulation of annexin-I or -V. Group II PLA₂ activity of glomerular mesangial cells stimulated by interleukin-1 β was enhanced by bile juice and various bile salts. In conclusion, activity of group II PLA₂ is upregulated partly due to enhanced transcription and translation in cirrhosis and is furthermore augmented by elevated levels of bile salts. (*J. Clin. Invest.* 1996; 98:365-371.) Key words: phospholipase A₂ • annexins • cirrhosis • mesangial cells • bile salts

Introduction

Cirrhotic patients have a cardiovascular disturbance characterized by low arterial pressure, high cardiac output, and in-

creased plasma volume (1-4). Besides arteriolar vasodilation and arteriovenous shunting, these patients exhibit a diminished sensitivity to pressor hormones and impaired hypoxic vasoconstriction (5-7). Eventually liver failure causes extrahepatic organ dysfunction such as hepatorenal or hepatopulmonary syndrome (8-10). These changes resemble those seen in patients or animals with septicemia (11-14).

Changes in arachidonic acid derived prostaglandins have been linked to hemodynamic alterations in cirrhotic disease states (11, 15-19). Renal perfusion and glomerular filtration are only maintained through the vasodilatory effect of prostaglandins. Inhibition of the cyclooxygenase enzyme results in a reduction of the effective renal plasma flow and sodium retention (20, 21) and administration of exogenous prostaglandin E derivatives enhance renal function of patients with cirrhosis (22). One of the rate limiting steps in the synthesis of prostaglandins is the release of arachidonic acid from membrane phospholipids by the enzyme phospholipase A₂ (PLA₂).¹ In contrast to the abundant literature about prostaglandins in liver cirrhosis, the relevance of PLA₂ has never been addressed. Therefore, in the present investigation we report the effect of biliary cirrhosis induced by bile duct ligation in rats on mRNA, protein levels and enzyme activity of group II PLA₂. The results revealed an upregulation of group II PLA₂ in cirrhosis.

Materials and Methods

Animals and bile duct excision. Sprague-Dawley male rats (Deutsche Versuchstierfarm Hartmann-Voss, Tuttlingen, Germany) were maintained on standard laboratory chow (Kliba-Futter, Basel, Switzerland) and tap water with a 12-h light-dark cycle at constant temperature and humidity. At the time of surgery, rats weighed 300 to 400 g. Animals were allotted to bile duct excision ($n = 7$) or sham surgery ($n = 5$). The experimental protocol had been approved by the Animal Ethics Committee of the state of Berne.

We used bile duct excision to produce cirrhosis (23). A 2-cm upper abdominal midline incision was made under ether anesthesia. In the experimental group, the bile duct was isolated and a 1-cm section excised after double ligation. In the sham group, the bowel and mesentery were manipulated and replaced. 8 wk after surgery the animals were anesthetized using pentobarbital sodium (50 mg/kg i.p.). In situ perfusion with ice-cold saline was performed. Liver and kidneys were removed and immediately frozen in liquid nitrogen, and stored at -80°C until further use.

Bile juice collection. Sprague-Dawley rats were anesthetized with pentobarbital sodium (50 mg/kg i.p.). The body temperature, mea-

Address correspondence to Brigitte M. Frey, Division of Nephrology, Department of Medicine, University of Berne, Freiburgstrasse 3, 3010 Berne, Switzerland. Phone: +41 31 632 31 44; FAX: +41 31 632 94 44.

Received for publication 15 November 1996 and accepted in revised form 25 April 1996.

1. Abbreviations used in this paper: CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; FCS, fetal calf serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; GLCA, glycolithocholic acid; IL-1 β , interleukin-1 β ; LCA, lithocholic acid; PLA₂, phospholipase A₂; RAS, Ribi Adjuvant system; RT, reverse transcription; TBS, Tris-buffered saline; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TS, Tris-sucrose buffer; TUDCA, taoursodeoxycholic acid.

sured by a rectal thermometer, was maintained at 37–37.5°C with a heating lamp. Bile juice was collected by cannulating the common bile duct with PE-50 tubing (0.51 × 0.94 mm).

Extraction of total RNA. Kidney and liver tissues frozen at –80°C were powdered using pestle and mortar kept in a mixture of dry ice and acetone. Total RNA was extracted from a known amount of tissue according to the method of Chomczynski and Sacchi (24). The RNA concentration was determined by absorbance at 260 nm. The quality of RNA was controlled by running an aliquot on a 1% agarose formaldehyde gel.

Reverse transcription of mRNA. The reverse transcription (RT) reaction mixture of 20 µl contained 50 mM Tris-HCl (pH 8.2), 6 mM MgCl₂, 10 mM DTT, 100 mM NaCl, 200 µM dNTPs, 11 U RNase inhibitor, 10 pmol primer (3' primer of the corresponding cDNA: positions 695–719 for group II PLA₂ cDNA [25], 335–359 for group I PLA₂ [26], 978–1007 for annexin-I [27], and 980–1004 for GAPDH [28] from Microsynth GmbH, Balgach, Switzerland), 2–5 µg of total RNA and 1 U of avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim Biochemicals, Rotkreuz, Switzerland). For competitive RT-PCR 18 fg of modified group II PLA₂ transcript was added to the reverse transcription reaction (29). Initially, the 3' primer and total RNA with and without modified group II PLA₂ transcript, were incubated together for 5 min at 65°C, and then cooled at room temperature for 15 min. The remaining reaction components, including avian myeloblastosis virus reverse transcriptase, were then added and incubated at 42°C for 60 min.

PCR. PCR was performed in a total volume of 30 µl with 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 200 µM dNTPs, 10 pmol of the appropriate 3' and 5' cDNA primers (5' primers of corresponding cDNA: positions 58–82 for group II PLA₂, 38–62 for group I PLA₂, 1–29 for annexin-I, and 66–90 for GAPDH), 6.0 µg BSA, 1 µCi [α -³²P]dCTP, 2–10 µl reverse transcribed cDNA, 1 U *Thermus aquaticus* DNA polymerase (Perkin Elmer Cetus Corp., Norwalk, CT). Before adding the enzyme and cDNA the samples were irradiated under ultraviolet light for 20 min to eliminate any contaminating DNA (30). The mixture was overlaid with mineral oil, and cDNA was amplified with a DNA thermal cycler (Perkin Elmer Cetus Instruments) for 35 cycles. The amplification profile involved denaturation at 94°C for 1 min and 15 s, primer annealing at 72°C for 2 min (group II PLA₂) or 62°C (group I PLA₂, annexin-I and GAPDH) and elongation of annealed primers at 72°C for 2 min (group II PLA₂) or for 3 min (group I PLA₂, annexin-I and GAPDH). 10 µl of each PCR reaction mixture were mixed with 2 µl of sixfold concentrated loading buffer and applied on either 1.5 or 0.9% agarose gels containing ethidium bromide. Electrophoresis was carried out in Tris-borate-EDTA buffer (pH 8.0) with a constant voltage of 8 V/cm for 40 min. Bands were visualized under ultraviolet light and excised from the gel. The radioactivity of the bands was measured in a scintillation counter using a Cerenkov program. Using the above mentioned primers the sizes of the fragment for different mRNA were 662 bp for group II PLA₂, 254 bp for modified group II PLA₂ transcript, 222 bp for group I PLA₂, 1,007 bp for annexin-I, and 939 for GAPDH.

Protein extraction. Small amounts of powdered tissue were extracted with acid according to the method of Märki and Franson (31). The prepared material designated as tissue acid extract was used to determine PLA₂ (group II) protein by Western blot analysis and enzyme activity. To determine specifically group IV PLA₂ protein by Western blot and its enzymatic activity, powdered tissue was extracted with Tris-sucrose (TS) buffer (10.0 mM Tris-HCl, pH 7.0; 25.0 mM sucrose). For the determination of annexin-I and -V by Western blot analysis powdered tissue was extracted with 10 mM Tris-HCl buffer, pH 9.0, containing 1% Triton X-100, 2 mM phenylmethylsulfonylfluoride and 5 mM EDTA using a Dounce homogenizer, stored on ice for 60 min. The extracts were centrifuged at 13,000 rpm at 4°C for 30 min to sediment cell debris. The supernatants from TS buffer and from Triton buffer were designated as TS extract and Triton extract, respectively.

Determination of protein concentrations. Protein concentration in tissue acid extract, TS extract and in Triton extract was determined

using the bicinchoninic acid protein assay reagent (Pierce Chemical Co., Rockford, IL).

Monoclonal antibodies. Rat lung tissues were extracted with acid according to the method of Märki and Franson (31). PLA₂ enzyme from lung acid extract was partially purified on a Sephadex G-50 column (dimensions 0.75 × 60 cm; elution buffer 50 mM sodium acetate buffer, pH 4.5, containing 1.5 M NaCl). The major PLA₂ fraction eluted in the 14-kD protein region were pooled and used to raise monoclonal antibody in mice.

Partially purified rat lung PLA₂ in a concentration of 1 mg/ml of saline was mixed with an equal volume of Ribi adjuvant system (RAS; RIBI Immunochem Research Inc., Hamilton, MT) and injected into the peritoneal cavity of 6-wk-old mice. Mice were boosted twice with 100 µg of PLA₂ in RAS and sacrificed 3 d after the last booster injection. The spleen was excised and somatic-cell fusion was performed by the method initially described by Koehlein and Milstein (32). Suspensions of fused cells in selective medium containing hypoxanthine, aminopterine, and thymidine were divided into 10 tissue culture plates (Falcon 3072; 96 wells/plate from Becton Dickinson Labware, Lincoln Park, NJ) at the rate of 200 µl/well. Samples of medium from each well were screened for anti-PLA₂ antibody activity using the dot blot procedure and Western blots. Cells from positive wells were subcloned by limiting dilution in 96-well tissue-culture plates. The selected clone (7G7) was expanded in vitro using Iscove's modified Dulbecco's medium enriched with 10% fetal calf serum. The monoclonal antibody was isolated from the hybridoma supernatants by protein G-Sepharose (Pharmacia Biotech AG, Duebendorf, Switzerland) affinity purification using buffers recommended by the manufacturer.

Monoclonal antibody (6G6) was prepared similarly using recombinant human annexin-I (33). Monoclonal antibodies against annexin-V and group IV PLA₂ were obtained from Alexis Corporation, (San Diego, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.

Western blot analysis. For Western blots indicated amounts of proteins from tissue acid extract (to detect group II PLA₂), Triton extract (to detect annexin-I and -V) and 50.0 µg of TS extract (to detect group IV PLA₂) were reduced (100 mM DTT) and denatured (100°C) before being resolved by 12.5 or 8.0% SDS-polyacrylamide gel electrophoresis (34). The proteins were transferred to PVDF Immobilon membrane (Millipore AG, Volketswil, Switzerland) by electroblot using Tris-glycine buffer containing 20% methanol. The transfer was performed at a constant voltage of 65 V for 60 min. Protein transfer was monitored by staining the Immobilon membrane with Ponceau S (Sigma Chemie, Buchs, Switzerland) and the gel with Coomassie blue. Purified recombinant annexin-I (0.94–7.5 ng) was used in each set of experiments as a standard to measure the annexin-I concentration in the protein samples. The blots were agitated with Tris-buffered saline (TBS), pH 7.5, containing 5% BSA for 60 min at room temperature, washed three times with TBS, and incubated with primary antibodies as follows.

To detect group II PLA₂ protein membranes were incubated for 120 min at 37°C with the monoclonal antibody 7G7 in TBS containing 1.0% Tween-20 and 0.05% BSA. To detect group IV PLA₂, annexin-I and -V membranes were incubated for 120 min at 37°C with their corresponding monoclonal antibodies in TBS containing 0.5% BSA. Membranes were washed three times with TBS and blocked again with TBS containing 5% BSA for 60 min at room temperature. Membranes were washed three times with TBS and incubated with peroxidase conjugated goat anti-mouse IgG (H + L) (Bio-Rad, Glattbrugg, Switzerland) for 60 min at room temperature in TBS containing 1% Tween-20 and 0.05% BSA for group II PLA₂ or in TBS containing 0.5% BSA for group IV PLA₂ and annexins. Membranes were washed three times with TBS and the peroxidase activity was determined using the enhanced chemiluminescence Western blotting detection system (Amersham International, Buckinghamshire, UK) according to the manufacturer's instructions. The bands on the X-ray films were scanned with a transmittance scanning densitometer (Scianalytics CSPI, MA).

Cell culture. Mesangial cells were cultured from isolated rat (Sprague-Dawley) glomeruli (35). Briefly, the cells were grown in RPMI 1640 supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 µg/ml) transferrin (5 µg/ml), insulin (5 µg/ml), and sodium selenite (5 ng/ml). For the experiments passages 27–30 of mesangial cells were used. Confluent mesangial cells cultured in 15-mm-diam wells (24 wells tissue culture plate; Falcon 3047) were incubated with 500 µl of RPMI 1640 medium containing 10% FCS and 1 nM of interleukin-1β (IL-1β; Pharma Biotechnologie, Hannover, Germany) with and without bile juice (5–50 µl/ml) or bile salts (100 µM) for 24 h at 37°C in a humidified atmosphere of 95% air and 5% CO₂. The following bile salts were tested: sodium salts of cholic acid (CA); chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), glycocholic acid (GCA), glycochenodeoxycholic acid (GCDC), glycolithocholic acid (GLCA), lithocholic acid (LCA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA), taurodeoxycholic acid (TDCA), and taurooursodeoxycholic acid (TUDCA) (Calbiochem AG, Lucerne, Switzerland). After 24 h incubation the medium was removed and centrifuged for 5 min at 4,000 rpm. The supernatant was removed and used for PLA₂ activity measurements.

Assay of PLA₂ activity. [³H]oleic acid (specific activity 10 Ci/mmol; Amersham International, Buckinghamshire, UK) labeled *Escherichia coli* and [³H]arachidonic acid (specific activity 205 Ci/mmol; Amersham International) labeled *E. coli* were prepared according to the procedure of Patriarca et al. (36). Group II PLA₂ was assayed using [³H]oleate-labeled, autoclaved *E. coli* as the substrate (37). The reaction mixture of 350 µl contained 100 mM Tris-HCl, pH 8.0, 5 mM Ca²⁺, 2.85 × 10⁸ cells of autoclaved *E. coli* (corresponding to 10,000 cpm and 5.5 nmol lipid phosphorus), and tissue acid extracts or supernatants of mesangial cells were incubated at 37°C for 120 min. Activity of group IV PLA₂ was assayed using [³H]arachidonate-labeled, autoclaved *E. coli* as the substrate for TS-extracted samples (38). The reaction mixture of 350 µl contained 100 mM Tris-HCl, pH 7.0, 1 mM Ca²⁺, 5.0 mM DTT, and TS-extract. This mixture was incubated for 60 min at 37°C. The reaction was started by adding autoclaved *E. coli* (2.1 × 10⁸ cells corresponding to 8,000 cpm and 4.0 nmol lipid phosphorus) and the incubation was continued for another 120 min at 37°C. The amount of protein was chosen such that hydrolysis of the substrate was 6–15%. The reaction was terminated by adding 100 µl of 2 N hydrochloric acid. Fatty acid-free BSA, (100 µl, 100 mg/ml) was added, and the tubes were vortexed and centrifuged at 13,000 g for 5 min. An aliquot (140 µl) of the supernatant containing released [³H]oleic acid or [³H]arachidonic acid was mixed with scintillation cocktail (Dynagel, J.T. Baker B.V., Deventer, Holland) and counted in a liquid scintillation counter (model SL 4000; Intertechnique, Nucleotron, Lausanne, Switzerland).

Statistics. All results in the text and in the figures are mean (+SD). Differences between two groups were analyzed by Student's *t*-test.

Results

All animals with bile duct ligation had hepatomegaly; the liver was nodular in appearance and all had portal hypertension. The animal characteristics are given in Table I.

The mean amount of total RNA isolated from liver and kidney (µg/g tissue) was significantly lower in cirrhotic liver (−27%) and kidney (−35%) tissue samples compared to their corresponding sham-operated controls. The mRNA of GAPDH and its activity have been shown to be unchanged during cirrhosis (39). Therefore the mRNA of GAPDH was used as an internal standard. In control and cirrhotic samples the mRNA of group I PLA₂, group II PLA₂, annexin-I and GAPDH were measured by RT-PCR. The mRNA of group II PLA₂ was additionally quantified by RT-PCR using a constant amount of a modified group II PLA₂ cDNA transcript. Both specific target mRNA and the modified transcript were coamplified in one

Table I. Characteristics of the Animals at the Time of the Experiments

	Controls (n = 5)	Bile duct ligation (n = 7)
Body weight (g)	500±20	404±38*
Liver weight (g)	18.8±1.4	32.4±2.5*
Kidney weight (g)	3.3±0.3	3.3±0.3*
Portal pressure (cm H ₂ O)	12.4±0.7	20.2±2.1*
Bilirubin (µmoles/l)	2±0	130±26*
Serum bile acids (µmoles/l)	3±2	91±51*
Alkaline phosphatase (IU/l)	155±41	605±288*
Alanine aminotransferase (IU/l)	47±4	100±37*

Mean±1 standard deviation are given. *Denotes a statistically significant difference (*P* < 0.05).

reaction using the same primers (29). Visual inspection of the bands on the agarose gels revealed qualitatively that mRNA of group II PLA₂ was increased in cirrhotic liver and kidney tissue when compared with their corresponding controls (data not shown). The inclusion and coamplification of the modified group II PLA₂ transcript using the same primers (29) excluded the possibility that increased concentrations of group II PLA₂ in cirrhotic rats were caused by an artifact during the PCR amplification procedure (40). An increased signal for annexin-I mRNA was observed in cirrhotic liver but not in kidney tissue (data not shown). In accordance with the previous report (39) no change in the mRNA of GAPDH was observed in cirrhotic liver and kidney tissue when compared with the corresponding controls in the present investigation. No signal for mRNA of group I PLA₂ was found in liver or in kidney tissue.

To assess quantitatively the change in mRNA, [α -³²P]dCTP was included during PCR and the incorporation of radioactivity into group II PLA₂, annexin-I and GAPDH was measured. The ratios between group II PLA₂ and GAPDH and the ratios between annexin-I and GAPDH were calculated. In sham-operated animals the liver contained more group II PLA₂ mRNA (difference between the mean values 213%, *P* < 0.006) than the kidney (Fig. 1). Cirrhosis induced transcription of group II PLA₂ mRNA in liver by 126% (*P* < 0.001) and in kidney tissue by 263% (*P* < 0.006; Fig. 1). Similar results were obtained when the ratio was calculated between group II PLA₂ and the modified transcript (128% increase in liver *P* < 0.05 and 381% increase in kidney *P* < 0.02). Compared to group II PLA₂ mRNA, cirrhosis exhibited a different effect on the mRNA of annexin-I. After the induction of cirrhosis annexin-I mRNA was increased in liver by 115% (annexin-I mRNA/GAPDH mRNA: control 0.86±0.37 vs cirrhotic 1.84±0.87, *P* < 0.05) tissue but unchanged in kidney tissue (annexin-I mRNA/GAPDH mRNA: control 1.98±0.5 and cirrhotic 1.83±0.72).

To establish whether the changes in group II PLA₂ and annexin-I mRNA due to cirrhosis were associated with corresponding changes of group II PLA₂ and annexin-I proteins, these proteins were analyzed together with annexin-V proteins in liver and kidney samples by Western blot using specific monoclonal antibodies (Fig. 2). In cirrhotic liver and kidney tissue increased amounts of group II PLA₂ but not annexin-I or -V proteins were found when compared with the corresponding control tissues (Fig. 2). In cirrhotic tissue samples




Figure 1. Measurements of group II PLA₂ mRNA, protein and enzyme activity in kidney and liver tissue samples. Messenger RNA was quantified from the ratio of group II PLA₂ cpm / GAPDH cpm. Increased PLA₂ mRNA was observed in cirrhotic liver ($P < 0.001$) and kidney tissues ($P < 0.006$). Group II PLA₂ protein was analyzed by Western blot analysis and the signals were determined by a transmission scanning densitometer. The relative transmission is plotted. PLA₂ protein was higher in liver ($P < 0.001$) and kidney tissues ($P < 0.001$) from cirrhotic than control animals. PLA₂ activity measured in liver and kidney acid extracts is expressed as nmol fatty acid/mg protein/min. The PLA₂ activity was increased following induction of cirrhosis in both liver ($P < 0.002$) and kidney tissue ($P < 0.02$). Open circles represent control ($n = 5$) and closed circles represent cirrhotic ($n = 7$) samples. The values are mean \pm SD.

group II PLA₂ protein was increased in liver by 230% ($P < 0.001$) and in kidney tissue by 690% ($P < 0.001$, Fig. 1). In these tissue samples group IV PLA₂ protein was also measured using a specific monoclonal antibody. Kidney tissue ex-




Figure 2. Western blot analysis of group II PLA₂ protein, annexin-I and -V from liver (A) and kidney (B) tissues from control (lane 1) and cirrhotic (lane 2) animals. Group II PLA₂ (0.5 μ g of tissue acid extract) was analyzed using 7G7 monoclonal antibody. Annexin-I (25 μ g of Triton-extract) was analyzed using 6G6 monoclonal antibody. Annexin-V (20 μ g of Triton extract for liver and 8 μ g for kidney) was analyzed using anti-annexin-V monoclonal antibody. In cirrhotic animals an increased amount of group II PLA₂ protein was found in

both kidney and liver tissues (see Fig. 1) but not of annexin-I (control vs cirrhotic: 109.0 ± 8.0 vs 118.0 ± 22.0 in liver and 78.0 ± 4.4 vs 79.0 ± 4.6 ng/mg protein in kidney tissue) or annexin-V protein (control vs cirrhotic: 27.7 ± 2.6 vs 27.2 ± 5.5 in liver and 8.96 ± 2.6 vs 11.0 ± 3.5 in kidney; for annexin-V protein the values are given as relative transmission).




Figure 3. Effect of bile juice and bile salts on IL-1 β stimulated PLA₂ activity in the supernatants of mesangial cells. Mesangial cells were incubated with 1 nM of IL-1 β in the presence or absence of indicated amounts of bile juice per 500 μ l or of 100 μ M of different bile salts for 24 h. Cell supernatants were adjusted to get 6–15% hydrolysis as described in the method section. Each value represents the mean of three determinations. PLA₂ activity is expressed as nmole fatty acid/ml of cell supernatant/min. GCA, glycocholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; TUDCA, taurooursodeoxycholic acid.

hibited a threefold higher amount of group IV PLA₂ protein than liver tissue ($P < 0.04$), however, cirrhosis did not influence the mean amount of group IV PLA₂ in these tissues (data not shown).

For the assessment of group II PLA₂ activity in liver and kidney tissue the PLA₂ enzyme from these tissues was solubilized by acid extraction. The extracted PLA₂ enzyme showed an optimum pH of 7.5–9.0 and required 5 mM Ca²⁺ for optimal activity (data not shown). The results from PLA₂ activity measurements are given in Fig. 1. As previously shown, liver exhibited a higher PLA₂ activity (487%, $P < 0.001$) than kidney tissue in control animals (29). PLA₂ activity was increased by 138% in liver ($P < 0.002$) and by 135% in kidney tissue ($P < 0.02$) when samples from cirrhotic animals were compared with those from control animals (Fig. 1). In the TS extract of these tissues group IV PLA₂ activity was measured using [³H]arachidonate-labeled *E. coli* in the presence of DTT (38). Control liver and kidney exhibited a 47- and 20-fold lower group IV PLA₂ activity when compared with group II PLA₂ activity (0.0133 ± 0.006 vs 0.63 ± 0.27 nmol fatty acid/mg protein/min in liver and 0.0148 ± 0.007 vs 0.29 ± 0.07 nmol fatty acid/mg protein/min in kidney tissues). Cirrhosis did not influence the group IV PLA₂ activity in these tissue samples (control vs cirrhosis: 0.0133 ± 0.006 vs 0.0162 ± 0.009 nmol fatty acid/mg protein/min in liver and 0.0148 ± 0.007 vs 0.0146 ± 0.005 nmol fatty acid/mg protein/min in kidney tissue).

When the ratio of group II PLA₂ mRNA/GAPDH mRNA was plotted versus the corresponding group II PLA₂ protein or activity for each animal separately the following correlation coefficients were found: mRNA vs protein 0.66 ($P < 0.02$) for liver and 0.65 ($P < 0.05$) for kidney; mRNA vs activity 0.59 ($P < 0.05$) for liver and 0.72 ($P < 0.01$) for kidney. Since there was no change in the activity of group IV PLA₂ and its protein content during cirrhosis the increased PLA₂ activity was most likely due to an increase in group II PLA₂ enzyme activity. The

direct relationships between mRNA, protein and activity supports the hypothesis that a defined enzyme was upregulated by biliary obstruction.

During biliary duct ligation the concentrations of bile salts increased (Table I). Therefore, the effect of bile juice and bile salts on the secreted group II PLA₂ enzyme from cultured mesangial cells stimulated by IL-1 β was studied. Bile juice or bile salts by themselves did not influence the transcription or secretion of mesangial cell PLA₂ enzyme. However, the activity of secreted PLA₂ by IL-1 β was enhanced by bile juice and various bile salts (Fig. 3). Bile juice increased PLA₂ activity in a dose-dependent manner. Maximum increased activity was observed at 10–25 μ l/ml of bile juice. At higher concentrations of bile juice, inhibition of PLA₂ activity was observed. Among various bile salts tested only GCA, TCA, TCDCA, TDCA, and TUDCA activated the IL-1 β -stimulated PLA₂ enzyme (Fig. 3). Other bile salts such as CA, CDCA, DCA, GCDCA, GLCA, and LCA did not influence the IL-1 β -stimulated PLA₂ activity (data not shown).

Discussion

PLA₂ enzymes characterized so far are classified into group I, II, III, and IV based on their primary and secondary structure (41,42). PLA₂ enzymes purified from human platelets and from human synovial fluid are classified under group II and are considered to account for inflammatory reactions, whereas the group I from pancreas appears not to be involved in inflammation (29, 43, 44). Group III enzyme has not been detected in mammals and the function of cytosolic PLA₂ (group IV) is not very well defined yet (42). Inflammatory human synovial fluid PLA₂ (group II) is resistant to low pH, optimally active in the presence of mM concentrations of calcium and at basic pH (38, 45). In the present study PLA₂ activity measured in the acid extracts of kidney and liver exhibited similar biochemical/biophysical properties as those known for PLA₂ derived from inflammatory synovial fluid PLA₂. Group IV PLA₂ selectively hydrolyzes *sn*-2-arachidonoyl-containing phospholipids and is resistant to reducing agents like DTT (38). Group IV PLA₂ activity measured in kidney and liver was 20–47-fold lower compared to the activity of group II PLA₂. Since no mRNA for group I PLA₂ was detected its contribution for total PLA₂ activity is very unlikely. Therefore the PLA₂ activity measured in these tissues corresponds mainly to group II PLA₂ enzyme.

The present investigation revealed an upregulation of group II PLA₂ enzyme in obstructive jaundice but not of group I or of group IV PLA₂. For such an enhanced PLA₂ activity three mechanisms have to be considered. First, an enhanced transcription and translation of the group II PLA₂ enzyme, second an increased concentration of PLA₂ activity enhancing agents and third, a decline of an endogenous PLA₂ inhibitor. The quantitative RT-PCR study revealed that group II PLA₂ mRNA levels were elevated after bile duct ligation in renal and liver tissue. The upregulation of PLA₂ was not a nonspecific phenomenon, since mRNA of GAPDH was unaffected and was used as internal standard. The increase of group II PLA₂ mRNA was reflected by an increase of group II PLA₂ protein and group II PLA₂ enzyme activity. Thus, an enhanced transcription and translation of group II PLA₂ enzyme accounted at least partly for the augmented enzyme activity in cirrhotic rats.

With respect to the second mechanism involving the PLA₂ activating agents during cirrhosis we analyzed the impact of bile juice and different bile salts known to be increased during cirrhotic conditions on the secretion and on the activation of group II PLA₂ enzyme activity. Bile juice and bile salts did not activate PLA₂ enzyme activity by inducing the transcription and translation of PLA₂ protein (data not shown). However, bile juice by itself and several bile salts like GCA, TCA, TCDCA, TDCA, and TUDCA individually activated IL-1 β released group II PLA₂ enzyme activity indicating the synergistic action of these salts. The present finding, that some bile acids enhance PLA₂ activity is novel, and in line with the description of other endobiotics such as PLA₂ activating protein enhancing PLA₂ activity (46).

For the third mechanism, a decline of an endogenous inhibitor of PLA₂ enzyme during cirrhosis, the role of the presumptive PLA₂ inhibitor annexin-I has been studied together with annexin-V. The annexin family presently consists of some 13 members capable of binding phospholipids in the presence of calcium (27, 47–49). It had been suggested that annexin-I (sive lipocortin-I or calpastatin-II) is a mediator of glucocorticoid action and acts as a specific inhibitor of PLA₂ (50, 51), a concept which remains controversial, however (33, 52). In the present investigation annexin-I and -V have been quantitatively assessed. Bile duct ligation did not affect the concentrations of these proteins. Thus, enhanced transcription of PLA₂ and subsequent activation by bile salts is the most likely factor accounting for the enhanced PLA₂ activity following bile duct ligation.

The mechanism accounting for the enhanced release of PLA₂ in obstructive cirrhosis is unknown; however, the following factors have to be considered. First, PLA₂ enzyme is activated by endotoxins and cytokines like IL-1 β and tumor necrosis factor- α (53–55). Chronic endotoxemia due to increased intestinal absorption and/or decreased hepatic clearance of lipopolysaccharide has been documented in patients with cirrhosis (56, 57) and may thus account for the activation of PLA₂. Second, glucocorticoids which are known to regulate the activity of group II PLA₂ enzyme could be involved in the observed activation of PLA₂. Glucocorticoid deficiency enhances and pharmacological doses reduce PLA₂ activity by means of inhibiting cAMP-dependent, but not cAMP-independent expression of group II PLA₂ mRNA (43, 58). The increased PLA₂ activity under glucocorticoid deficiency was positively correlated to the decreased expression of the presumptive inhibitor annexin-I (29). Since there was no change in the level of annexin-I during cirrhosis, the enhanced PLA₂ activity in biliary obstruction is probably not related to deranged glucocorticoid effects. Third, activation of PLA₂ by catecholamines and angiotensin II has to be considered (59). Numerous studies have demonstrated an increased release of both pressor agents in humans and various animal models with cirrhosis (60, 61), suggesting a role of these endobiotics for PLA₂ activation in liver disease.

Arachidonate metabolites have been reported to be involved in liver damage. For instance there is evidence for 16,16, dimethyl PGE₂ to attenuate liver cell damage induced by carbon tetrachloride and aflatoxin (62–64). Similarly, a PGI₂ analogue protects against carbon tetrachloride or acetaminophen-induced liver injury (65, 66) and 5-lipoxygenase inhibitors or LT receptor antagonists reduce liver injury from D-galactosamine (67–71). On the other hand, there is evidence that

leukotrienes and thromboxane could play a major role in the pathogenesis of cirrhosis and portal hypertension. Thus, the demonstration of increased leukotriene excretion by patients with liver cirrhosis is compatible with PLA₂ activation (72). This contention is further supported by the presence of elevated prostacyclin levels in patients with cirrhosis which correlate with portal hypertension (73).

While the role of prostanooids in the liver is ambiguous, at least exogenous prostaglandins being protective but leukotrienes, prostacyclin, and thromboxane being pathogenetically involved in cirrhogenesis and maintenance of portal hypertension and hyperdynamic circulation, the situation appears much clearer in the kidney. Through their vasodilator effect, prostaglandins modify intrarenal vascular resistance and thereby maintain glomerular filtration rate (74). Furthermore, they promote natriuresis and free water clearance (20, 22). This explains the deleterious effect of cyclooxygenase inhibitors on renal function in cirrhosis (75).

In conclusion, our studies demonstrate an upregulation of group II PLA₂ at the enzyme and message level in biliary cirrhosis in rat kidney and liver. While this could account for the renal protective effects of prostaglandins in the kidney, its role in cirrhogenesis in the liver remains to be established.

Acknowledgments

Supported by grants from the Swiss National Foundation for Scientific Research to F.J. Frey and B.M. Frey (No. 32-40492.94) and to J. Reichen (No. 32.30168.90)

References

1. Kowalski, H.J., and W.H. Abelmann. 1953. Cardiac output at rest in Laennec's cirrhosis. *J. Clin. Invest.* 32:1025-1033.
2. Murray, J.F., A.M. Dawson, and S. Sherlock. 1958. Circulatory changes in chronic liver disease. *Am. J. Med.* 24:358-367.
3. Lieberman, F.L., and T.B. Reynolds. 1967. Plasma volume in cirrhosis of the liver. Its relation to portal hypertension, ascites and renal failure. *J. Clin. Invest.* 46:1297-1308.
4. Arroyo, V., J. Bosch, M. Mauri, F. Ribera, F. Navarro-Lopez, and J. Rodes. 1981. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. *Eur. J. Clin. Invest.* 11:221-229.
5. Daoud, F.S., J.T. Reeves, and J.W. Schaefer. 1972. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. *J. Clin. Invest.* 51:1076-1080.
6. Ames, R.P., A.J. Borkowski, A.M. Sicinski, and J.H. Laragh. 1965. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. *J. Clin. Invest.* 44:1171-1186.
7. Schroeder, E.T., G.H. Anderson, S.H. Goldman, and D.H.P. Streeten. 1976. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. *Kidney Int.* 9:511-519.
8. Krowka, M.J., and D.A. Cortese. 1990. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. *Hepatology* 11:138-142.
9. Davidson, E.W., and M.J. Dunn. 1987. Pathogenesis of the hepatorenal syndrome. *Annu. Rev. Med.* 38:361-372.
10. Green, J., and O.S. Better. 1995. Systemic hypotension and renal failure in obstructive jaundice - mechanistic and therapeutic aspects. *JASN* 5:1853-1871.
11. Ohara, N., N.F. Voelkel, and S-W. Chang. 1993. Tissue eicosanoids and vascular permeability in rats with chronic biliary obstruction. *Hepatology* 18: 111-118.
12. Reeves, J.T., and R.R. Grover. 1974. Blockade of acute hypoxic pulmonary hypertension by endotoxin. *J. Appl. Physiol.* 36:328-332.
13. Chang, S., C.O. Feddersen, P.M. Henson, and N.F. Voelkel. 1987. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. *J. Clin. Invest.* 79:1498-1509.
14. Parker, M.M., J.H. Shelhamer, C. Natanson, W. Alling, and J.E. Parillo. 1987. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. *Crit. Care Med.* 15:923-929.
15. Zipser, R.D., J.C. Hoefs, P.F. Speckart, P.K. Zia, and R. Horton. 1979. Prostaglandins: modulator of renal function and pressor resistance in chronic liver disease. *J. Clin. Endocr. Metab.* 48:895-900.
16. Bruix, J.J., D. Bopsch, R. Kravetz, R. Mastai, and J. Rodes. 1985. Effects of prostaglandin inhibition of systemic and hepatic hemodynamics in patients with cirrhosis of the liver. *Gastroenterology*. 88:430-435.
17. Zipser, R.D., G.H. Radvan, I.J. Kronborg, R. Duke, and T.E. Little. 1983. Urinary thromboxane B₂ and prostaglandin E₂ in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. *Gastroenterology*. 84:697-703.
18. Guarner, F., C. Guarner, J. Prieto, I. Colina, J. Quiroga, J. Casas, R. Freixa, J. Rosello, E. Gelpi, and J. Balanzo. 1986. Increased synthesis of systemic prostaglandin in cirrhotic patients. *Gastroenterology*. 90:687-694.
19. Moore, K., P.S. Ward, G.W. Taylor, and R. Williams. 1991. Systemic and renal production of thromboxane A₂ and prostacyclin in decompensated liver disease and hepatorenal syndrome. *Gastroenterology*. 100:1069-1077.
20. Raymond, K.H., and M.D. Lifschitz. 1986. Effect of prostaglandins on renal salt and water excretion. *Am. J. Med.* 80:22-33.
21. Dibona, G.F. 1986. Prostaglandins and nonsteroidal anti-inflammatory drugs. Effects on renal hemodynamics. *Am. J. Med.* 80:12-21.
22. Wong, F., D. Massie, P. Hsu, and F. Dudley. 1994. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. *Gastroenterology*. 106:658-663.
23. Gross, J.B. Jr., J. Reichen, T.B. Zeltner, and A. Zimmermann. 1987. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. *Hepatology*. 7:457-463.
24. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156-159.
25. Ishizaki, J., O. Ohara, E. Nakamura, M. Tamaki, T. Ono, A. Kanda, N. Yoshida, H. Teraoka, H. Tojo, and M. Okamoto. 1989. cDNA cloning and sequence determination of rat membrane-associated phospholipase A₂. *Biochem. Biophys. Res. Commun.* 162:1030-1036.
26. Ohara, O., M. Tamaki, E. Nakamura, Y. Tsuruta, Y. Fjuii, M. Shin, H. Teraoka, and M. Okamoto. 1986. Dog and rat pancreatic phospholipases A2: Complete amino acid sequences deduced from complementary DNAs. *J. Biochem.* 99: 733-739.
27. Wallner, B.P., R.J. Mattaliano, C. Hession, R.L. Cate, R. Tizard, L.K. Sinclair, C. Foeller, E.P. Chow, J.L. Browning, K.L. Ramachandran, and R.B. Pepinsky. 1986. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. *Nature (Lond.)*. 320:77-81.
28. Muller, S., and H.J. Seitz. 1994. Cloning of a cDNA for the FAD-linked glycerol-3/phosphate dehydrogenase from rat liver and its regulation by thyroid hormones. *Proc. Natl. Acad. Sci. USA* 91:10581-10585.
29. Vishwanath, B.S., F.J. Frey, M.J. Bradbury, M.F. Dallman, and B.M. Frey. 1993. Glucocorticoid deficiency increases phospholipase A₂ activity in rats. *J. Clin. Invest.* 92:1974-1980.
30. Sarkar, G., and S.S. Sommer. 1990. Shedding light on PCR contamination. *Nature (Lond.)*. 343:27.
31. Märki, F., and R. Franson. 1986. Endogenous suppression of neutral-active and calcium-dependent phospholipase A₂ in human polymorphonuclear leukocytes. *Biochim. Biophys. Acta*. 879:149-156.
32. Koehler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature (Lond.)*. 256:495-497.
33. Frey, B.M., F.J. Frey, V.R. Lingappa, and H. Trachsel. 1991. Expression of human recombinant lipocortin I in a wheat-germ cell-free system and *Xenopus* oocytes. *Biochem. J.* 275:219-225.
34. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. SDS-polyacrylamide gel electrophoresis of proteins. In *Molecular Cloning: A Laboratory Manual*. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 18.47-18.59.
35. Lovett, D.H., R.B. Sterzel, M. Kashgarian, and J.L. Ryan. 1983. Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. *Kidney Int.* 23:342-349.
36. Patriarca, P., S. Beckerdite, and P. Elsbach. 1972. Phospholipases and phospholipid turnover in *Escherichia coli* spheroplasts. *Biochim. Biophys. Acta*. 260:593-600.
37. Vishwanath, B.S., C.A. Fux, D.E. Uehlinger, B.M. Frey, R.C. Franson, and F.J. Frey. 1996. Hemodialysis activates phospholipase A₂ enzyme. *Nephrol. Dial. Transplant.* 11:109-116.
38. Marshall, L.A., and A. Rosak. 1993. Coexistence of two biochemically distinct phospholipase A₂ activities in human platelet, monocyte, and neutrophil. *Biochem. Cell Biol.* 71:331-339.
39. Elsing, C., J. Reichen, U. Marti, and E.L. Renner. 1994. Hepatocellular Na⁺/H⁺ exchange is activated at transcriptional and posttranscriptional level in rat biliary cirrhosis. *Gastroenterology*. 107:468-478.
40. Wang, A.M., M.V. Doyle, and D.F. Mark. 1989. Quantification of mRNA by the polymerase chain reaction. *Proc. Natl. Acad. Sci. USA*. 86:9717-9721.
41. Hendrikson, R.L., E.T. Kreuger, and P.S. Keim. 1977. Amino acid sequence of phospholipase A₂-alpha from the venom of *Crotalus adamanteus*. *J.*

Biol. Chem. 252:4913–4921.

42. Mayer, R.J., and L.A. Marshall. 1993. New insights on mammalian phospholipase A₂(s); comparison of arachidonoyl-selective and -nonselective enzymes. *FASEB J.* 7:339–348.

43. Nakano, T., O. Ohara, H. Teraoka, and H. Arita. 1990. Group II phospholipase A₂ mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. *FEBS Lett.* 261:171–174.

44. Buchler, M., P. Malfertheiner, and H. Schadlich. 1989. Role of phospholipase A₂ in human acute pancreatitis. *Gastroenterology*. 97:1521–1526.

45. Kramer, R.M., C. Hession, B. Johanson, G. Hayes, P. McGraw, E.P. Chow, R. Tizard, and R.B. Pepinsky. 1989. Structure and properties of a human non-pancreatic phospholipase A₂. *J. Biol. Chem.* 264:5768–5775.

46. Steiner, M.R., J.S. Bomalaski, and M.A. Clark. 1993. Responses of purified phospholipases A₂ to phospholipase A₂ activating protein (PLAP) and melittin. *Biochim. Biophys. Acta*. 1166:124–130.

47. Flower, R.J., and G.J. Blackwell. 1979. Anti-inflammatory steroids induce biosynthesis of a phospholipase A₂ inhibitor which prevents prostaglandin generation. *Nature (Lond.)*. 278:456–459.

48. Blackwell, G.J., R. Carnuccio, M. Di Rosa, R.J. Flower, L. Parente, and P. Persico. 1980. Macro cortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. *Nature (Lond.)*. 287:147–149.

49. Goulding, N.J., and P.M. Guyre. 1993. Glucocorticoids, lipocortins and the immune response. *Curr. Opin. Immunol.* 5:108–113.

50. Cirino, G., S.H. Peers, R.J. Flower, J.L. Browning, and R.B. Pepinsky. 1989. Human recombinant lipocortin-1 has acute local antiinflammatory properties in the rat paw edema test. *Proc. Natl. Acad. Sci. USA*. 86:3428–3432.

51. Sautebin, L., R. Carnuccio, A. Ialenti, and M. Di Rosa. 1992. Lipocortin and Vasocortin-2 species of antiinflammatory proteins mimicking the effect of glucocorticoid. *Pharmacol. Res.* 25:1–12.

52. Davidson, F.F., E.A. Dennis, M. Powell, and J.R. Glenney, Jr. 1987. Inhibition of phospholipase A₂ by "lipocortins" and calpactins. *J. Biol. Chem.* 262:1698–1705.

53. Glaser, K.B., R. Asmis, and E.A. Dennis. 1990. Bacterial lipopolysaccharide priming of P388D₁ macrophage-like cells for enhanced arachidonic acid metabolism. *J. Biol. Chem.* 265:8658–8664.

54. Nakazato, Y., M.S. Simonson, W.H. Herman, M. Konieczkowski, and J.R. Sedor. 1991. Interleukin-1 α stimulates prostaglandin biosynthesis in serum-activated mesangial cells by induction of a non-pancreatic (type II) phospholipase A₂. *J. Biol. Chem.* 266:14119–14127.

55. Schalwijk, C.G., J. Pfeilschifter, F. Märki, and H. Van den Bosch. 1991. Interleukin-1 β , tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A₂ in rat mesangial cells. *Biochem. Biophys. Res. Commun.* 174:268–275.

56. Prytz, H., J. Holst-Christensen, B. Korner, and H. Liehr. 1976. Portal venous and systemic endotoxemia in patients without liver disease and systemic endotoxemia in patients with cirrhosis. *Scand. J. Gastroenterol.* 11:857–863.

57. Clemente, C., J. Bosch, J. Rodes, V. Arroyo, A. Mas, and S. Maragall. 1977. Functional renal failure and hemorrhagic gastritis associated with endotoxemia in cirrhosis. *Gut*. 18:556–560.

58. Nakano, T., and H. Arita. 1990. Enhanced expression of group II phospholipase A₂ gene in the tissues of endotoxin shock rats and its suppression by glucocorticoids. *FEBS Lett.* 273:23–26.

59. Leyen, S.A.V., M.F. Romero, M.C. Khosla, and J.G. Douglas. 1993. Modulation of phospholipase A₂ activity and sodium transport by angiotensin-(1-7). *Kidney Int.* 44:932–936.

60. Bosch, J., V. Arroyo, A. Betriu, A. Mas, F. Carrilho, F. Rivera, F.N. Lopez, and J. Rodés. 1980. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. *Gastroenterology*. 78:92–99.

61. Nicholls, K.M., M.D. Shapiro, V.J. VanPutten, R. Kluge, H.M. Chung, D.G. Bichet, and R.W. Schrier. 1985. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates- and suppressibility by central volume expansion. *Cir. Res.* 56:457–461.

62. Rush, B.D., K.F. Wilkinson, N.M. Nichols, R. Ochoa, M.N. Brunden, and M.J. Ruwart. 1989. Hepatic protection by 16,16-dimethyl prostaglandin E₂ against acute aflatoxin B₁-induced injury in the rat. *Prostaglandins*. 37:683–693.

63. Stachura, J., A. Tarnawski, K.J. Ivey, T. Mach, J. Bogdal, J. Szczudrawa, and B. Klimczyk. 1981. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. *Gastroenterology*. 81:211–217.

64. Ruwart, M.J., B.D. Rush, N.M. Friedle, R.C. Piper, and G.J. Kolaja. 1981. Protective effects of 16,16-dimethyl PGE₂ on the liver and kidney. *Prostaglandins*. 21:97–102.

65. Bursch, W., and R. Schulte-Hermann. 1986. Cytoprotective effect of the prostacyclin derivative iloprost against liver cell death induced by hepatotoxin carbon tetrachloride and bromobenzene. *Klin. Wochenschr.* 64:47–50.

66. Guarner, F., N.K. Boughton-Smith, G.F. Blackwell, and S. Moncada. 1988. Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. *Hepatology*. 8:248–253.

67. Keppler, D., W. Hagemann, S. Rapp C. Denzlinger, and H.K. Koch. 1985. The relation of leukotrienes to liver injury. *Hepatology*. 5:883–891.

68. Tiegs, G., and A. Wendel. 1988. Leukotriene-mediated liver injury. *Biochem. Pharmacol.* 37:2569–2573.

69. Hagemann, W., A.M. Steffan, A. Kirn, and D. Keppler. 1987. Leukotriene as mediators in frog virus 3-induced hepatitis in rats. *Hepatology*. 7:732–736.

70. Wender, A., and G. Tiegs. 1987. Leukotriene D₄ mediates galactosamine/endotoxin-induced hepatitis in mice. *Biochem. Pharmacol.* 36:1867.

71. Shiratori, Y., H. Moriwaki, Y. Muto, H. Onishi, M. Kato, and F. Asano. 1989. Production of leukotriene B₄ in parenchymal and sinusoidal cells of the liver in rats treated simultaneously with D-galactosamine and endotoxin. *Gastroenterol. Jpn.* 24:640–645.

72. Uemura, M., U. Buchholz, H. Kojima, A. Keppler, P. Hafkemeyer, H. Fukui, T. Tsujii, and D. Keppler. 1994. Cysteinyl leukotrienes in the urine of patients with liver diseases. *Hepatology*. 20:804–812.

73. Hashizume, M., K. Inokuchi, and K. Tanaka. 1985. The role of prostacyclin in patients with portal hypertension. *Liver*. 5:89–93.

74. Dunn, M.J. 1984. Role of eicosanoids in the control of renal function in severe hepatic disease. *Gastroenterology*. 87:1392–1395.

75. Brater, D.C., S.A. Anderson, and D.B. Cartwright. 1987. Reversible acute decrease in renal function by NSAIDs in cirrhosis. *Am. J. Med. Sci.* 294:168–174.